Chalk River, Ontario, January 26, 2026
Two Years of Progress
This year marks the third anniversary of Actineer, the joint venture between ITM Isotope Technologies Munich SE (ITM) and Canadian Nuclear Laboratories (CNL). Over the past two years, the partnership has taken meaningful steps to establish an efficient operating model based on its corporate structure and long-term strategy, positioning the joint venture to support the growing global demand for Actinium-225 (Ac-225).
Strengthening the Operational Model
As Actineer enters its third year, the partners have formalized new strategic agreements that clarify and enhance their respective roles.
As a global leader in the GMP production of Lutetium-177 (Lu-177), ITM will lead the sales, marketing, global distribution and GMP compliance at Actineer. ITM will apply its long-standing expertise in quality control, customer engagement and regulatory excellence to fulfill this responsibility.
CNL will provide interim Ac-225 production and exclusive access to a reliable Radium-226 (Ra-226) supply, the raw material expected to become a critical determinant of future Ac-225 production capacity. With its strong background in the development of innovative nuclear science and technology products and services, CNL will reinforce Actineer’s ability to scale sustainably.
These agreements ensure a coordinated, scalable framework that supports the joint venture’s long-term vision and mission to supply the radiopharmaceutical industry with a dependable supply of Actinium-225.
